A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
CA 2473707 A1 · Owner: Aventis Pharmaceuticals Inc. · Inventors: Sandrasagra, Anthony; Eishingdrelo, Haifeng; Cai, Jidong
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Provided herein is a novel and useful G-protein coupled receptor that is involved in signal transduction with respect to inflammation and physiological immunological response. Also provided are methods of using the receptor to screen for molecules that may modulate the activity of the receptor. Such molecules may readily have applications in treating a plethora of inflammation and immunologically related diseases and disorders.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 21, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 21, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 21, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.